Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI and BOP

Periodontitis Clinical Trial

Official title:

Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on Plaque, Gingival Inflammation and Bleeding Upon Probing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05258721
• Other study ID #: ATSU-RPR-Oral rinse 2020
• Status: Completed
• Phase: Phase 2
• Start date: July 6, 2021
• Est. completion date: October 31, 2022

Study information

• Verified date: January 2023
• Source: Rowpar Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

90-day, self-controlled, longitudinal, non-blinded clinical trial which will measure changes in clinical parameters in participants with gingivitis and Stage I or II periodontitis who apply ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse.

Description:

The study will be conducted with 60 medically healthy participants between ages 18 to 75 years with gingival or periodontitis (Stage I or II) who are receiving routine preventive care and/or periodontal maintenance.

Subjects will brush with ClōSYS® Sensitive Fluoride Toothpaste twice daily and rinse with ClōSYS® Sensitive Rinse twice daily after brushing.

The primary response variables will be the Subjects' scores on the Plaque Index (PI), Gingival Index (GI) and the number of sites with bleeding upon probing (BOP). Probing depths and clinical attachment level will be assessed at baseline and 3 months. Adverse events will also be assessed and documented at each visit. In addition, Subjects will keep a usage diary documenting their daily use of the toothpaste and oral rinse and any comments or observations regarding usage or adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: October 31, 2022
• Est. primary completion date: October 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subjects are between the ages of 18 to 80 years

• Subjects have a minimum of 20 permanent teeth, excluding third molars

• Subjects have been diagnosed with gingivitis or periodontitis (Stages I and II are based on the level of CAL and Bone Loss (BL). The diagnosis is Stage I if: (a) BL is less than 15% and (b) CAL is between 1-2mm. The diagnosis is Stage II if: (a) BL is between 15% and 33% and (b) CAL is between 3-4mm)

• Subjects exhibit bleeding upon probing in >20% of sites

• Subject is seen every 3 months for routine dental prophylaxis/periodontal maintenance

• Subjects do not have a significant medical history or metabolic diseases (diabetes with A1C = 7.0, pregnancy)

• Subject is currently a non-smoker or has discontinued smoking at least 6 months prior to enrollment

• Subject agrees to refrain from use of the following products: Peridex®, PerioGuard®, Listerine®, Cepacol®, Crest Pro-Health® rinse, Colgate Total® rinse, Colgate Total® toothpaste, Crest Pro Health® toothpaste, or any generic equivalent while participating in this study. Alcohol is not the active ingredient in any oral rinse product and does not produce a significant antibacterial effect

• Subject is able to read and provide written informed consent

• Subject is able to follow verbal and/or written instructions, perform oral hygiene procedures and return to the test facility for specified study examinations

• Subject agrees not to receive a dental "cleaning" (prophylaxis) while in the study

• Subject must permanently reside in Arizona

Exclusion Criteria:

• Subject has significant medical history or poorly controlled/uncontrolled diabetes (as defined above)

• Subject is pregnant

• Subject has a medical condition that requires antibiotic premedication prior to dental treatment

• Subject has taken antibiotics within 1 month of study enrollment

• Subject who takes multiple medications and/or herbal and dietary supplements known to alter bleeding and exhibits/reports spontaneous gingival bleeding

• Subject takes medications that may interfere with study results (eg. antibiotics, steroids, immunosuppressants, high dose aspirin (325+ mg/day), chemotherapy and/or radiation therapy for cancer).

• Subject is a current smoker

• Subject has a history of non-surgical or surgical periodontal therapy within 6 months of study participation

• Subject has Stage III or IV periodontitis, Grade B or C

• Subject is currently taking or in the past 28 days has taken another investigational drug or participated in other investigational studies that may impact study outcomes

• Subject has not had a dental cleaning within six months prior to the start of the study

Related Conditions & MeSH terms

• Gingivitis
• Hypersensitivity
• Periodontitis

Intervention

Drug:
• CloSYS® Sensitive Fluoride Toothpaste
CloSYS® Sensitive Fluoride Toothpaste is an over-the-counter drug product containing 0.12% stabilized chlorine dioxide (sodium chlorite in an aqueous solution) and 0.13% w/v fluoride ion.

Other:
• CloSYS® Sensitive Rinse
CloSYS® Sensitive Rinse is a cosmetic product containing 0.1% stabilized chlorine dioxide.

Locations

Country	Name	City	State
United States	Arizona School of Dentistry & Oral Health	Mesa	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Rowpar Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Modified Gingival Index (MGI)	MGI uses a rating score between 0 and 4, with 0 indicating a tooth with healthy gums and 4 the most severe inflammation. MGI scores were determined by visual exam of the gingiva on 4 surfaces for each tooth present except for third molars, for a total of 28 teeth. The total number of teeth exhibiting inflammation affecting all portions of the gingival unit (Score = 2) were noted at each visit. The total number of teeth affected was evaluated for each visit in the final analysis.; At baseline: Score range is (0-64) At 12 weeks: Score range is (0-32)	Baseline and 12 weeks
Primary	Changes in Plaque Index (PI)	The PI was recorded on all teeth except for third molars. PI was recorded on 4 surfaces of each tooth. PI uses a rating score between 0 and 3, with 0 indicating no plaque in gingival area and 3 heavy accumulation of plaque. Total score is reported.; At baseline: Score range is 9 -157. At 12 weeks: Score range is 1 -147.	Baseline and 12 weeks
Primary	Changes in Probing Depths (PD)	PD at six sites per tooth for all teeth	90 Days
Primary	Changes in Clinical Attachment Level (CAL)	CAL will be measured from the CEJ to the base of the pocket at 6 sites per tooth	90 Days
Primary	Changes in Bleeding On Probing (BOP)	Bleeding On Probing (BOP) will be recorded as a dichotomous variable (present/absent) during the periodontal examination. The percentage of sites that bleed will be calculated by dividing the number of sites with bleeding by the total number of sites.	Baseline and 12 weeks
Secondary	Adverse Events	Adverse events will be collected throughout the study	90 Days